Bronchiolitis Obliterans Syndrome
15
4
6
6
Key Insights
Highlights
Success Rate
86% trial completion
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 52/100
6.7%
1 terminated out of 15 trials
85.7%
-0.8% vs benchmark
13%
2 trials in Phase 3/4
33%
2 of 6 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 6 completed trials
Clinical Trials (15)
LAM-001 in Lung Transplant Recipients With Bronchiolitis Obliterans Syndrome.
Alvelestat (MPH966), an Oral Neutrophil Elastase Inhibitor, in Bronchiolitis Obliterans Syndrome After Allogeneic Hematopoietic Stem Cell Transplantation
Novel Pulmonary Function Measures for Diagnosis of Bronchiolitis Obliterans Syndrome Following Hematopoietic Stem-Cell Transplantation in Children
BElumosudil for Bronchiolitis Obliterans Prevention/Therapy (BEBOP)
The Longitudinal Impact of Respiratory Viruses on Bronchiolitis Obliterans Syndrome After Allogeneic Hematopoietic Cell Transplantation (The RV-BOS Study)
Safety and Efficacy of Itacitinib in Participants With Bronchiolitis Obliterans Syndrome Following Lung Transplantation
Extension Trial on Efficacy / Safety of L-CsA + SoC in Treating BOS in Post Single or Double Lung Transplant (BOSTON-3)
Early Detection and Management of Bronchiolitis Obliterans Syndrome Following Pediatric Hematopoietic Stem Cell Transplantation
Imaging and Understanding BOS in Lung Transplantation
Ruxolitinib for Newly Diagnosed Bronchiolitis Obliterans Syndrome
Evaluation of Electrical Impedance Tomography for the Diagnosis of Chronic Rejection in Lung Transplants Recipients
Correlation of Lung Biopsy, BAL, and High Resolution CT Scan in Lung Transplantation
Forced Oscillation Versus Spirometry in Diagnosing Post Pulmonary Transplant Bronchiolitis Obliterans Syndrome
Azithromycin in Bronchiolitis Obliterans Syndrome
Characterization of Bronchiolitis-obliterans Syndrome (BOS) Following Lung Transplantation